The 35 new pQTLs overlap with several loci of biomedical relevance, including a trans-pQTL for ANGPTL6 at the COLEC11 locus associated with low-density lipoprotein (LDL)-cholesterol levels, a trans-pQTL for BRE (brain and reproductive organ expressed (TNFRSF1A modulator)) at the CFH locus associated with age-related macular degeneration and immunoglobulin (Ig)A nephropathy, a cis-pQTL for galactosylceramidase associated with inflammatory bowel disease and many others that can now be considered as candidate drug targets for these diseases. This evidence concerns the gene CD79A and kidney disorder.